Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.
Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005. Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir can be more severe than other anti-retrovirals. Some side effects include intracranial hemorraging, hepatitis, and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.
References
This article is licensed under the GNU Free Documentation License.
Last updated on Wednesday May 28, 2008 at 06:27:15 PDT (GMT -0700)
View this article at Wikipedia.org - Edit this article at Wikipedia.org - Donate to the Wikimedia Foundation
Copyright © 2008, Dictionary.com, LLC. All rights reserved.